Janus kinase inhibition in Down syndrome: 2 cases of therapeutic benefit for alopecia areata

Angela L Rachubinski, Belinda Enriquez Estrada, David Norris, Cory A Dunnick, Jennifer C Boldrick, Joaquin M Espinosa, Angela L Rachubinski, Belinda Enriquez Estrada, David Norris, Cory A Dunnick, Jennifer C Boldrick, Joaquin M Espinosa

No abstract available

Keywords: AA, alopecia areata; DS, Down syndrome; Down syndrome; IFN, interferon; JAK, Janus kinase; Janus kinase inhibition; STAT, signal transducer activator of transcription; T21, trisomy 21; Xeljanz; alopecia areata; atopic dermatitis; autoimmunity; eczema; interferon; tofacitnib; trisomy 21; vitiligo.

Figures

Fig 1
Fig 1
Young woman with DS and AA treated with tofacitinib for nearly 3 years. Pictures show rapid hair recovery during tofacitinib treatment.
Fig 2
Fig 2
Adolescent male with DS and AA treated with tofacitinib. Note the rapid hair recovery during the initial 2 months of tofacitinib treatment.

References

    1. Madan V., Williams J., Lear J.T. Dermatological manifestations of Down's syndrome. Clin Exp Dermatol. 2006;31(5):623–629.
    1. Sureshbabu R., Kumari R., Ranugha S., Sathyamoorthy R., Udayashankar C., Oudeacoumar P. Phenotypic and dermatological manifestations in Down Syndrome. Dermatol Online J. 2011;17(2):3.
    1. Sullivan K.D., Lewis H.C., Hill A.A. Trisomy 21 consistently activates the interferon response. eLife. 2016;5
    1. Sullivan K.D., Evans D., Pandey A. Trisomy 21 causes changes in the circulating proteome indicative of chronic autoinflammation. Sci Rep. 2017;7(1):14818.
    1. Islam N., Leung P.S., Huntley A.C., Gershwin M.E. The autoimmune basis of alopecia areata: a comprehensive review. Autoimmun Rev. 2015;14(2):81–89.
    1. Schepis C., Barone C., Siragusa M., Pettinato R., Romano C. An updated survey on skin conditions in Down syndrome. Dermatology. 2002;205(3):234–238.
    1. Marmon S., De Souza A., Strober B.E. Psoriasis and Down syndrome: a report of three cases and a potential pathophysiologic link. Dermatol Online J. 2012;18(6):13.
    1. Hall J.C., Rosen A. Type I interferons: crucial participants in disease amplification in autoimmunity. Nat Rev Rheumatol. 2010;6(1):40–49.
    1. Shreberk-Hassidim R., Ramot Y., Zlotogorski A. Janus kinase inhibitors in dermatology: A systematic review. J Am Acad Dermatol. 2017;76(4):745–753.e719.
    1. O'Shea J.J., Kontzias A., Yamaoka K., Tanaka Y., Laurence A. Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis. 2013;72(Suppl 2):ii111–ii115.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe